🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT03847857
Active, not recruiting Phase 3

Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage (PLACE030)

NCT03847857 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-sen University
Phase
Phase 3
Started
2019-02-21
Last updated
2025-06-12

Condition(s) studied

Esophageal Anastomotic Leak

Investigational drug(s) / intervention(s)

Porcine Fibrin Sealant (PFS)McKeown esophagectomy

Porcine Fibrin Sealant (PFS): McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.

McKeown esophagectomy: McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.

Study summary

The primary objective is to evaluate the efficacy and assess the role of Porcine Fibrin Sealant (Bioseal®) in preventing cervical anastomotic leakage after esophagectomy in the patients with resectable thoracic esophageal cancer and gastroesophageal junction cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Histologic diagnosis of squamous cell carcinoma or adenocarcinoma of thoracic esophageal carcinoma or gastroesophageal junction cancer with Stage T1-4aN0-3M0, according to 8th edition of Union for International Cancer Control (UICC) staging system 2. More than 6 months of expected survival 3. Age ranges from 18 to75 years 4. Absolute white blood cells count ≥4.0×109/L, neutrophil ≥1.5×109/L, platelets ≥100.0×109/L, hemoglobin ≥90g/L, and normal functions of liver and kidney. 5. WHO performance status (PS) of 0-1 6. Informed consent will be obtained before the study Exclusion Criteria: 1. Patients who have undergone definitive chemoradiotherapy 2. Patients with concomitant hemorrhagic disease 3. Patients with other uncontrollable status that cannot tolerate surgery 4. Patients with known hypersensitivity to the porcine fibrin sealant product 5. Pregnant or breast feeding 6. Patients cannot signed the informed consent document because of psychological quality, family and social factors 7. Patients with concomitant peripheral neuropathy, whose CTC status is 2 or even more 8. Have a history of diabetes over 10 years and with poorly controlled blood sugar level 9. Patients with serious cardiac, respiratory, hepatic, renal,hematologic, immunological disease or cachexy, who cannot tolerate surgery

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Sun Yat-sen University Cancer Center Guangzhou Guangdong
Jieyang Affiliated Hospital, Sun Yat-sen University Jieyang Guangdong
Cancer Hospital of Shantou University Medical College, Shantou Shantou Guangdong
Zhongshan Peoples Hospital Zhongshan Guangdong
Sichuan Cancer Hospital Chengdu Sichuan
Shanghai Chest Hospital Shanghai China

More Sun Yat-sen University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03847857 on ClinicalTrials.gov ↗ ← All trials in China